Bellerophon Pulse Technologies: Clinical Trials

2 completed. 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	2	Completed 2

Follow Bellerophon Pulse Technologies: new trials by email

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device - Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease	Phase 2	Completed	Bellerophon Pulse Technologies	159	2012-12-01	2023-02-27
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device - Pulmonary Arterial Hypertension, Pulmonary Hypertension	Phase 2	Completed	Bellerophon Pulse Technologies	80	2012-04-01	2023-02-27

Conditions studied

Hypertension, Pulmonary (2)  ·  Pulmonary Arterial Hypertension (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Countries

United States (2)  ·  Canada (1)

Top investigators

Ashika Ahmed, MD (2)